Xeris Biopharma Holdings Inc (XERS)
3.09
+0.05
(+1.64%)
USD |
NASDAQ |
Nov 22, 16:00
3.085
0.00 (0.00%)
After-Hours: 20:00
Xeris Biopharma Holdings Cash from Operations (Quarterly): -8.305M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -8.305M |
| June 30, 2024 | -10.35M |
| March 31, 2024 | -20.30M |
| December 31, 2023 | 7.471M |
| September 30, 2023 | -14.61M |
| June 30, 2023 | -13.74M |
| March 31, 2023 | -26.14M |
| December 31, 2022 | -16.12M |
| September 30, 2022 | -17.75M |
| June 30, 2022 | -20.61M |
| March 31, 2022 | -48.41M |
| December 31, 2021 | -28.95M |
| September 30, 2021 | -22.61M |
| June 30, 2021 | -20.02M |
| March 31, 2021 | -23.96M |
| December 31, 2020 | -10.87M |
| Date | Value |
|---|---|
| September 30, 2020 | -16.98M |
| June 30, 2020 | -23.76M |
| March 31, 2020 | -28.94M |
| December 31, 2019 | -29.57M |
| September 30, 2019 | -30.58M |
| June 30, 2019 | -23.04M |
| March 31, 2019 | -21.15M |
| December 31, 2018 | -18.34M |
| September 30, 2018 | -15.92M |
| June 30, 2018 | -14.22M |
| March 31, 2018 | -7.805M |
| December 31, 2017 | -9.10M |
| September 30, 2017 | -5.577M |
| June 30, 2017 | -6.467M |
| March 31, 2017 | -3.519M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-48.41M
Minimum
Mar 2022
7.471M
Maximum
Dec 2023
-19.73M
Average
-20.16M
Median
Cash from Operations (Quarterly) Benchmarks
| Zevra Therapeutics Inc | -18.14M |
| NovaBay Pharmaceuticals Inc | -2.061M |
| Palatin Technologies Inc | -7.016M |
| iBio Inc | -3.715M |
| Theriva Biologics Inc | -3.913M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 9.914M |
| Cash from Financing (Quarterly) | -0.083M |
| Free Cash Flow | -32.26M |
| Free Cash Flow Per Share (Quarterly) | -0.0563 |
| Free Cash Flow to Equity (Quarterly) | -9.195M |
| Free Cash Flow to Firm (Quarterly) | -2.952M |
| Free Cash Flow Yield | -7.25% |